Skip to main content

Amersham Reports Increase in Q3 Revenues

NEW YORK, Oct. 29 (GenomeWeb News) - Amersham PLC, which General Electric is slated to acquire pending regulatory approval, today reported increased third quarter sales.

 

The London-based company's sales for the quarter came to £393 million ($668.3 million) up from £378 million for the same period last year.

 

Broken down by business, sales in Amersham Health came to £235 million, compared to £222 million in the second quarter of last year, and sales in Amersham Biosciences were nearly flat at £158 million, compared to £156 million for the same period in 2002. 

 

Amersham said the increase in Biosciences revenue came from growth in the protein separations business, for which it said revenues were £67 million this quarter, while sales in discovery systems were £91 million.   The company said that proteomics and bioassay area grew, while it experienced "continued weakness in the sequencing market," and that CodeLink sales steadily increased.

 

Furthermore, the company said that the restructuring program that it announced in February was proceeding ahead of schedule, "and is on track to deliver profitability as planned during 2004."

 

Amersham did not report income, expenses, or assets for the quarter.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.